The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Cancers can spread to the lung causing fluid build-up and requires drainages in hospital that are painful and costly. Surgery is previously seen as the definitive option to stop fluid forming, but is invasive with complications. Indwelling pleural catheter (IPC) is a novel implanted device inside the chest that allows patients to drain fluid at home. AMPLE Trial-3 is the first multicenter randomized clinical trial to compare surgery vs IPC to provide fluid control and improve quality of life.
Food Allergy In The First 15 Year Of Life: Wave 5 Of The HealthNuts Longitudinal Study
Funder
National Health and Medical Research Council
Funding Amount
$2,435,075.00
Summary
Understanding why some food allergy persists into adolescence is critical because adolescents are at highest risk of life-threatening allergic reactions. Food allergy also has lifelong impacts on children's health. HealthNuts is a longitudinal study of 5300 children that measured allergic diseases from infancy. At the age 15 follow-up, we will identify predictors of food allergy persistence and severity, and the consequences of infant food allergy on later respiratory health.
Providing Translatable Evidence To Advance Prevention And Management Of COPD: A Longitudinal Study From The 1st To 7th Decade Of Life
Funder
National Health and Medical Research Council
Funding Amount
$2,893,320.00
Summary
Chronic obstructive pulmonary disease (COPD) makes breathing difficult and reduces wellbeing. People are more likely to get COPD from the age of 60 years, but we do not know why and who. Our study will develop tools to identify early who will develop COPD by 60 years. We will also develop a tool to identify 60-year-old individuals whose lung function is declining faster than normal. These findings will help us to better prevent and manage COPD.
Prospective Ovarian Cancer Cohort To Authenticate Stratification Of Prognosis In Ovarian Tumours (POCCA-SPOT)
Funder
National Health and Medical Research Council
Funding Amount
$993,580.00
Summary
Ovarian cancer has poor survival, with less than 40% of women surviving 5 years. There is a wide range of survival, but very few characteristics that indicate which patients will do well or poorly. We have developed a tumour test at diagnosis, that can predict prognosis at 5 years. In newly diagnosed cases, we will test tumours to predict prognosis and then determine the accuracy and assess patient acceptability. This study will lead to clinical use of the test and improve treatment decisions.
The Effect Of High SPF Sunscreen Application On Vitamin D
Funder
National Health and Medical Research Council
Funding Amount
$1,175,123.00
Summary
Sunscreen prevents sunburn and skin cancer, and current guidelines are that it should be routinely used when the maximum UV index is forecast to reach at least 3. However, applying sunscreen in laboratory experiments reduces vitamin D production, and there is concern that regular application of high SPF sunscreens might increase the risk of vitamin D deficiency. We propose a randomised controlled trial to determine if adhering to the current guidelines decreases vitamin D.
Anti-PD 1 Brain Collaboration + Radiotherapy Extension: The ABC-X Study
Funder
National Health and Medical Research Council
Funding Amount
$1,010,141.00
Summary
The purpose of this research study is to determine whether administering radiotherapy to melanoma brain tumours, in combination with 2 drugs called nivolumab and ipilimumab(also known as Immunotherapy), will be more effective than treating brain tumours with immunotherapy. Patients in this trial will be randomly assigned to 1 of 2 treatment groups. Group 1 will receive radiotherapy to their melanoma brain lesion(s), combined with immunotherapy. Group 2 will receive immunotherapy treatment alone.